Eupraxia Pharmaceuticals annual return on equity
2023
2024
2025
Eupraxia Pharmaceuticals Return on Equity (ROE) Growth & History (EPRX)
Eupraxia Pharmaceuticals's return on equity was −66.83% for fiscal 2025.
View full Eupraxia Pharmaceuticals company overviewEupraxia Pharmaceuticals annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −66.83% | +76.36 pp |
| 2024 | 2024-12-31 | −143.19% | +421.07 pp |
| 2023 | 2023-12-31 | −564.26% | — |
Eupraxia Pharmaceuticals quarterly return on equity
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −10.77% | +23.40 pp |
| Q1 2026 | 2026-03-31 | −11.51% | +10.30 pp |
| Q4 2025 | 2025-12-31 | −19.42% | — |
| Q3 2025 | 2025-09-30 | −11.30% | — |
| Q2 2025 | 2025-06-30 | −34.17% | — |
| Q1 2025 | 2025-03-31 | −21.81% | — |
Eupraxia Pharmaceuticals return on equity trends
Between the periods ended 2023-12-31 and 2025-12-31, Eupraxia Pharmaceuticals's return on equity increased from −564.26% to −66.83%, a change of +497.43 percentage points. The latest reported quarter, Q2 2026, shows −10.77%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Eupraxia Pharmaceuticals source filings ↗